Plaque Psoriasis 
The MD Magazine Plaque Psoriasis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

FDA Approves Inflectra, Biosimilar for All Indications
The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.
Men afflicted with psoriasis are more likely to suffer from erectile dysfunction.
The FDA has approved ixekizumab (Taltz/Eli Lilly) for moderate to severe plaque psoriasis. It is administered by injection.
Researchers have discovered new Lyme disease-causing bacteria, Borrelia mayonii (B. mayonii) in the upper Midwest. Infection may trigger nausea, vomiting, and a more widespread rash, officials say.
Researchers are closing in on a medical treatment for wart-like skin growths know as seborrheic keratosis.
Age matters when it comes to patients’ access to psoriasis treatment.
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
Graded drug challenges are considered the gold standard for evaluating patients with a low-risk history of a prior adverse drug reactions – like a mild rash or unknown reaction to penicillin as a child.
Seniors who developed the painful rash commonly known as shingles may also be at higher risk of suffering a stroke or heart attack.

Most Popular


$vacMongoViewPlus$ $vAR$